$244.01+4.20 (+1.75%)
Phillips 66 operates as an integrated downstream energy provider in the United States, the United Kingdom, Germany, and internationally.
Phillips 66 in the Energy sector is trading at $244.01 with a market capitalization of $97.4B. Wall Street consensus targets $222.00 (19 analysts), implying a -9.0% move over the next 12 months. The stock is currently near its 52-week high of $246.95, remaining 45.6% above its 200-day moving average. On fundamentals, Piotroski 7/9 indicates strong financial quality, Altman Z in the safe zone. The Whystock Score of 100/100 reflects bullish alignment across trend, valuation and analyst targets.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $51.00Bβ | $32.54Bβ | $34.11Bβ | $34.52Bβ | $33.32B |
| Gross Profit | $6.75Bβ | $2.77Bβ | $4.15Bβ | $3.47Bβ | $3.43B |
| Operating Income | $4.28Bβ | $114.00Mβ | $1.62Bβ | $965.00Mβ | $1.19B |
| Net Income | $3.85Bβ | $207.00Mβ | $2.91Bβ | $133.00Mβ | $877.00M |
Phillips 66 operates as an integrated downstream energy provider in the United States, the United Kingdom, Germany, and internationally. It operates through five segments: Midstream, Chemicals, Refining, Marketing and Specialties (M&S), and Renewable...

PSX combines profitable refining conditions with stable midstream cash flows, helping limit exposure to commodity price volatility.

Phillips 66 (NYSE:PSX) was held by 69 hedge funds at the end of Q2 2026 in the Insider Monkey database, with a total stake value of just over $5.6 billion. This is up from 64 hedge fund holders with a cumulative investment of just over $5.5 billion in the previous quarter. Strong Refining Margins Set [β¦]

CVE stands out versus PSX with a lower valuation, rising oil sands output, improving efficiency and a stronger balance sheet.

Phillips 66's 17.5% monthly rally rides on stronger refining margins and midstream growth, but valuation and lower 2027 earnings temper the upside.

Delek US Holdings has surged past its own analyst targets after a stunning 215% one-year run, and its CEO just said all options are on the table. The question is whether any strategic buyer can still justify the price.